The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

The present invention concerns a DNA-replication-associated (Rep) protein comprising an amino acid sequence as depicted in SEQ ID NO: 11 or 12; (b) a fragment of SEQ ID NOs:11 or 12 which is capable of binding an anti-Rep antibody specific for a protein having the amino acid sequence of SEQ ID NOs: 11 or 12; or (c) an amino acid sequence having a 90% or more homology to the amino acid sequence of (a) or (b) and is capable of binding an anti-Rep antibody specific for a protein having an amino acid sequence of SEQ ID NOs:11 or 12. The present invention further concerns a method of diagnosing MS or a predisposition for MS and a kit for use in such methods.

The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

The present invention includes compositions, methods, and methods of making and using a polymer-encased nanodisc comprising: one or more integral membrane proteins in a lipid layer; and a polymer comprising zwitterionic styrene-maleic acid derivative repeating units that carry zero or nearly zero negative charge, and the polymer-encased nanodiscs.

Provided herein is a molecular robot comprising (v) a molecular motor composed of a first nucleic acid scaffold and a functional core with a catalytic center of an ATP-driven motor embedded therein; (vi) an ion channel; (vii) a hollow drillhead composed of a second nucleic acid scaffold; and (viii) at least two rods, wherein each rod is composed of a third nucleic acid scaffold and at least one aptamer on its distal end, and wherein each rod is connected to the molecular motor via its proximal end.

The present invention provides novel mitochondrial fusion transcripts and related deletion molecules that are associated with UV exposure. Methods for in vivo and in vitro detection of mtDNA molecules and associated fusion transcripts is also provided, as is their use in the screening and testing of skin care products.

Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.

Disclosed herein are Notch transcriptional activation complex kinase (MACK) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (Ia) and pharmaceutically acceptable salts thereof: wherein the substituents are as described. ##STR00001##